Wockhardt up 12% as HP drug controller revokes suspension

Image
Press Trust of India Mumbai
Last Updated : Apr 28 2014 | 5:17 PM IST
Shares of pharmaceutical firm Wockhardt Ltd today surged nearly 12 per cent after the company said Himachal Pradesh drug regulator has revoked the suspension imposed on sale and manufacturing of a combination medicine used for treatment of pain.
Wockhardt's scrip rose sharply by 11.73 per cent to settle at Rs 721.80 on the BSE. In intra-day, the stock climbed 14.55 per cent to Rs 740.
At the NSE, the scrip soared 11.42 per cent to Rs 722.
In terms of volume, 18.87 lakh shares of the company changed hands at the BSE, while over 57 lakh shares were traded at the NSE during the day.
"The State Drug Controller, Himachal Pradesh, has now revoked the suspension and accordingly the company will continue to manufacture, sell and distribute the fixed dose combination (FDC) of cicyclomine hydrochloride IP 10mg, tramadol hydrochloride IP 50mg and acetamenophen IP 325mg," Wockhardt said in a filing to the BSE.
Last week, the company had said Himachal Pradesh state drug controller has suspended the manufacture, sale or distribution of the said FDC medicine.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 28 2014 | 5:17 PM IST

Next Story